Advisory Committee
Prof. Peter Szlosarek
http://www.bci.qmul.ac.uk/staff/item/peter-szlosarek
Dr Peter SzlosarekMD, PhD
Centre: Molecular Oncology
Reader in Medical Oncology
p.w.szlosarek@qmul.ac.uk
QMUL Directory
My main research interest is in exploring why argininosuccinate synthetase (ASS1), a rate-limiting enzyme in L-arginine synthesis, is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy.
I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers including ADAM, TRAP and ATOMIC clinical studies.
http://www.bci.qmul.ac.uk/staff/item/peter-szlosarek
Dr Peter SzlosarekMD, PhD
Centre: Molecular Oncology
Reader in Medical Oncology
p.w.szlosarek@qmul.ac.uk
QMUL Directory
My main research interest is in exploring why argininosuccinate synthetase (ASS1), a rate-limiting enzyme in L-arginine synthesis, is aberrantly expressed in human cancers and how this knowledge may be exploited for anticancer therapy.
I lead an active translational programme from bench to bedside of the arginine-depleting agent ADI-PEG20 in several hard-to-treat cancers including ADAM, TRAP and ATOMIC clinical studies.
|
|
|
Tim-Benepal
Consultant Medical Oncologist at St George's and Parkside Hospital |
|
Dr Jason Lester is a Consultant Clinical Oncologist
|
Mary MulhallSenior Associate
|